2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Pathogenesis, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4391 Population-level socioeconomic burden of chronic lymphocytic leukemia after introduction of targeted therapy: Evidence from europe and Canada

Goran Bencina, Emanuele Guardalben, MD2, Jes Deol3, Edward OIiver4, Yunni Yi5, Anne Meiwald6, Manfred Welslau7
1 Eli Lilly and Company, Indianapolis, United States
2 Eli Lilly and Company, Indianapolis, United States
3 Adelphi Values Ltd, Bollington, United Kingdom
4 Adelphi Values Ltd, Bollington, United Kingdom
5 Adelphi Values Ltd, Bollington, United Kingdom
6 Adelphi Values Ltd, Bollington, United Kingdom
7 MVZ am Klinikum Aschaffenburg, Aschaffenburg, Germany
BACKGROUND: The treatment landscape for chronic lymphocytic leukemia (CLL) has evolved substantially over the past two decades, progressing from chemotherapy to chemoimmunotherapy and, more recently, to targeted therapies. Targeted therapies have markedly improved survival outcomes as well as yielding quality of life gains relative to earlier standards of care but carry an increased direct treatment cost. Despite these therapeutic advances, the population-level impact on disease burden as measured by disability-adjusted life years (DALYs) and associated indirect economic costs have not been systematically evaluated across treatment eras and healthcare settings. DALYs, a composite metric capturing both years of life lost due to premature mortality (YLLs) and years lived with disability (YLDs), provide a comprehensive measure of disease burden and facilitate cross national comparisons. The Global Burden of Disease (GBD) study offers a harmonized framework for such analyses, enabling robust comparisons across countries and time periods. Most existing economic literature on CLL has focused on direct treatment costs, leaving the broader population-level societal burden across therapeutic eras unquantified. This study has estimated the population-level socioeconomic burden and indirect cost of CLL across different treatment eras in 4 countries and quantified the residual burden of disease. METHODS: Annual DALYs attributable to CLL in Canada, France, Germany, and the United Kingdom (UK) from 2003-2019 were obtained from the Institute for Health Metrics and Evaluation GBD dataset. Country and year specific DALYs were multiplied by GDP per capita to estimate population-level indirect cost. A scenario analysis used country specific 2024 value of a statistical life year (VSLY) to reflect a broader socioeconomic perspective. Values were aggregated into three 5-year treatment eras: chemotherapy (2003-2007), chemoimmunotherapy (2009-2013), and targeted therapy (2015-2019), with a gap year between eras to allow for adoption lag. Data from 2020 onward were excluded to avoid COVID-19 related distortion. All costs are reported in 2024 US dollars. RESULTS: Across the 4 countries, the indirect cost of CLL was stable at $33.1B and $33.2B (629,225 and 631,476 DALYs) in the chemotherapy and chemoimmunotherapy eras respectively. All countries had a minor change in indirect cost between -0.5% to 1.3% from the chemotherapy to the chemoimmunotherapy era. With the introduction of targeted therapies, the socioeconomic burden across the 4 countries fell to $28.7B (543,138 DALYs), representing an absolute reduction of 88,338 DALYs and 68,801 YLLs compared to the chemoimmunotherapy era.  This corresponds to a total savings of approximately $4.5B over the 5 years - equivalent to nearly $1B in annual savings and an average 13.6% reduction in indirect cost (UK -16.3%, $1.0B; Canada -14.2%, $635M; Germany -13.1%, $1.9B; France -11.9%, $943M). Valuing burden using VSLY produced an even larger effect with a reduction of $10.4B in targeted therapy era, equivalent to over $2B in annual savings.

 

CONCLUSIONS: This is the first study to systematically quantify the population-level burden of CLL using longitudinal real-world data from the harmonized cross national GBD framework. The introduction of targeted therapies was accompanied by a clear and consistent reduction in the societal burden and indirect cost of CLL driven by improved survival (a reduction of 68,801 YLLs versus the chemoimmunotherapy era), corresponding to nearly $1B cost reduction annually across 4 countries when valued using GDP per capita and over $2B annually under a broader socioeconomic perspective. These findings demonstrate that the higher direct costs of targeted therapies could be potentially partially offset by reductions in the indirect societal burden of CLL, an economic benefit missed by analyses focused on direct treatment cost alone. The residual burden of $28.7B (GDP-based) in the targeted therapy era indicates that current therapies have not eliminated the population-level impact of CLL, highlighting continued unmet need for therapies and management with improved efficacy, tolerability and quality of life to further reduce the population-level burden of CLL.
Emanuele Guardalben, MD: Eli Lilly and Company - Current Employment